Integrating FIB-4 into routine primary care pathways may improve early identification and referral of patients at risk of advanced fibrosis in MASLD.<h4>Conclusion</h4> These findings highlight the importance of proactive screening in high-risk individuals, even when liver enzymes are normal, as reliance on biochemistry alone may overlook clinically significant fibrosis; incorporating tools such as FIB-4 and the AST:ALT ratio can facilitate earlier identification and timely intervention. The gene discussed is GPT; the disease is fibrosis.